GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Institutional Ownership

Circio Holding ASA (OSL:CRNA) Institutional Ownership : 0.26% (As of Jun. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Circio Holding ASA's institutional ownership is 0.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Circio Holding ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Circio Holding ASA's Float Percentage Of Total Shares Outstanding is 0.00%.


Circio Holding ASA Institutional Ownership Historical Data

The historical data trend for Circio Holding ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Institutional Ownership Chart

Circio Holding ASA Historical Data

The historical data trend for Circio Holding ASA can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.32 0.30 0.30 0.30 0.29 0.28 0.28 0.26 0.26 0.26

Circio Holding ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Circio Holding ASA (OSL:CRNA) Business Description

Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines